Treatment options for metastatic colorectal cancer in patients with liver dysfunction due to malignancy
Open Access
- 1 July 2017
- journal article
- review article
- Published by Elsevier BV in Critical Reviews in Oncology/Hematology
- Vol. 115, 59-66
- https://doi.org/10.1016/j.critrevonc.2017.03.029
Abstract
No abstract availableKeywords
This publication has 61 references indexed in Scilit:
- Trends in colorectal cancer mortality in Europe: retrospective analysis of the WHO mortality databaseBMJ, 2015
- Safety and efficacy of FOLFOX followed by cetuximab for metastatic colorectal cancer with severe liver dysfunction.Journal of the National Comprehensive Cancer Network, 2014
- Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trialThe Lancet Oncology, 2013
- Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patientsAnnals of Oncology, 2011
- XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated resultsBritish Journal of Cancer, 2011
- Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS studyAnnals of Oncology, 2011
- Capecitabine plus oxaliplatin (XELOX) versus 5‐fluorouracil/leucovorin plus oxaliplatin (FOLFOX‐6) as first‐line treatment for metastatic colorectal cancerInternational Journal of Cancer, 2010
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal CancerThe New England Journal of Medicine, 2004
- Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the national cancer institute organ dysfunction working groupSeminars in Oncology, 2003
- High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancerEuropean Journal of Cancer and Clinical Oncology, 1988